"Mark Diamond, Antisense Therapeutics CEO said, “These positive effects on the above proteins strengthens ATL1102’s profile in the treatment of both non-ambulant and ambulant DMD patients while positioning it as an exciting prospective therapeutic approach in other muscle and fibrotic conditions. We are excited about this new data and the emerging opportunities that present to expand our development of ATL1102 in DMD and other disease applications in a strategic manner.”
Ann: New data supports ATL1102s broader clinical potential, page-2
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.3¢ |
Change
0.004(5.80%) |
Mkt cap ! $65.81M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.3¢ | 7.0¢ | $16.42K | 231.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 7.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.3¢ | 63510 | 1 |
View Market Depth
| Last trade - 16.10pm 01/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.2¢ |
Change
0.004 ( 2.86 %) |
||||
| Open | High | Low | Volume | ||
| 7.0¢ | 7.2¢ | 7.0¢ | 38700 | ||
| Last updated 13.48pm 01/05/2024 ? | |||||
| PER (ASX) Chart |